Antibodies for
Immunohistochemistry
MUC5AC (MRQ-19)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45232 IMPATH MUC5AC RTU M (MRQ-19)
50 Tests
44342 MUC5AC RTU M (MRQ-19)
7 ml Ready To Use
44704 MUC5AC 0,1 M (MRQ-19)
100 µl liquid Concentrated
44705 MUC5AC 1 M (MRQ-19)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Stomach
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Mucins are high molecular weight glycoproteins which constitute the major component of the mucus layer that protects the gastric epithelium.
The heterogeneous pattern of mucin expression, including the expression of the intestinal mucin MUC2, may provide new insights into the
differentiation pathways of gastric carcinoma. Pinto-de-Sousa et al. have shown, in a comprehensive study of gastric carcinomas evaluated
for expression of several mucins (MUC1, MUC2, MUC5AC and MUC6), that: (1) mucin expression is associated with tumor type (MUC5AC
with diffuse and infiltrative carcinomas and MUC2 with mucinous carcinomas) but not with the clinico-biological behavior of the tumors; and (2)
mucin expression is associated with tumor location (MUC5AC with antrum carcinomas and MUC2 with cardia carcinomas), indirectly reflecting
differences in tumor differentiation according to tumor location. The following generalities apply to the patterns of MUC5AC expression:
Preferentially expressed in the normal stomach and respiratory tract; esophageal carcinomas – 67%, gastric carcinomas – 58%, colonic
carcinomas – 6%-25%, pancreatic ductal carcinomas – 73%, cholangiocarcinomas – 45%, endocervical adenocarcinomas – 70%, endometrial
adenocarcinomas – 22%, and lung adenocarcinomas – 14%.
Mucin Expression in Neoplasms
MUC5AC
MUC1
MUC2
MUC6
Pancreatic
Adenocarcinoma
+
+
-
-
Cervical Adenocarcinoma
+
+
-
-
Paget Extramammary
+
+
-
-
Cholangiocarcinoma
+/-
+
-
-
Pan Intraductal Pap Ca
+
-
+
+
Appendiceal
Adenocarcinoma
+
-
+
-
Barrett Esophagus
+
+
+
-
Panc. Mucinous Cystic
+
-
-
-
Breast Colloid Carcinoma
-
+
+
+
Mucins Expression in Organs
MUC5AC
MUC1
MUC2
MUC4
MUC6
Stomach
+
+
-
+
+
Small Intestine
-
-
+
-
+
Colon
-
-
+
-
Pancreas
-
+
-
-
+
Reference
1. Chaves P, et al. Dis Esophagus. 2005; 18(6):383-7.
170
